Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of irinotecan liposome plus eribulin in second-line or later small round cell sarcoma
ChiCTR2600122769Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome and eribulin in small round cell sarcoma (SRBCT), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Maximum tolerated dose (MTD). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
irinotecan liposomeeribulin
03
Conditions
small round cell sarcoma (SRBCT)
Beyond the preview
Go deeper on ChiCTR2600122769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122769.